Home/Filings/4/0001209191-23-048632
4//SEC Filing

Auster Martin 4

Accession 0001209191-23-048632

CIK 0001851194other

Filed

Sep 6, 8:00 PM ET

Accepted

Sep 7, 4:31 PM ET

Size

8.8 KB

Accession

0001209191-23-048632

Insider Transaction Report

Form 4
Period: 2023-09-05
Auster Martin
Chief Financial Officer
Transactions
  • Sale

    Common Stock

    2023-09-05$32.26/sh18,327$591,18329,322 total
  • Sale

    Common Stock

    2023-09-05$33.41/sh8,142$272,04921,180 total
  • Sale

    Common Stock

    2023-09-05$33.98/sh3$10221,177 total
Footnotes (3)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2022.
  • [F2]Represents the weighted average share price of an aggregate total of 18,327 shares sold in the price range of $31.97 to $32.8321. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F3]Represents the weighted average share price of an aggregate total of 8,142 shares sold in the price range of $32.97 to $33.96. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Issuer

Ventyx Biosciences, Inc.

CIK 0001851194

Entity typeother

Related Parties

1
  • filerCIK 0001875786

Filing Metadata

Form type
4
Filed
Sep 6, 8:00 PM ET
Accepted
Sep 7, 4:31 PM ET
Size
8.8 KB